PMID- 24993498
OWN - NLM
STAT- MEDLINE
DCOM- 20160706
LR  - 20211021
IS  - 1436-3305 (Electronic)
IS  - 1436-3291 (Linking)
VI  - 18
IP  - 3
DP  - 2015 Jul
TI  - HER2 expression in locally advanced gastric cancer with extensive lymph node 
      (bulky N2 or paraaortic) metastasis (JCOG1005-A trial).
PG  - 467-75
LID - 10.1007/s10120-014-0398-3 [doi]
AB  - BACKGROUND: Human epidermal growth factor receptor 2 (HER2) is likely 
      overexpressed and/or amplified in locally advanced gastric cancer with extensive 
      (bulky N2 or paraaortic) lymph node metastasis, and patients may benefit from 
      treatment with anti-HER2 antibodies. This study evaluated the frequency of HER2 
      overexpression and amplification in The Japanese Gastric Cancer Association 
      (JGCA)-N3 and JGCA-bulky N2 tumors and the correlation between HER2 status and 
      survival. METHODS: HER2 status was assessed using immunohistochemistry (IHC) and 
      fluorescence in situ hybridization (FISH) in tumor tissue samples from 89 
      patients with gastric adenocarcinoma enrolled in the phase II JCOG0001 and 
      JCOG0405 trials. HER2 positivity was defined as IHC3+ or IHC2+ with confirmatory 
      FISH results. RESULTS: Of the 89 tumor samples, 24 (27 %) showed HER2 positivity, 
      including 16 scored as IHC3+ and 8 as IHC2+ and FISH positive. Multivariate 
      analysis showed that the HER2 positivity rate was significantly higher in 
      evaluable differentiated tumors than in undifferentiated tumors [18/44 (40.9 %) 
      vs. 5/42 (11.9 %)]. Although the apparent OS curve of HER2 positive was superior 
      to that of HER2 negative patients, HER2 status was not a statistically 
      significant prognostic factor in multivariate analysis. CONCLUSION: The HER2 
      positivity rate was relatively high in patients with JGCA-bulky N2 and JGCA-N3 
      gastric adenocarcinoma, suggesting that HER2 evaluation is essential to select 
      the therapeutic regimen for neoadjuvant chemotherapy for this group of patients.
FAU - Matsumoto, Tomohiro
AU  - Matsumoto T
AD  - Department of Upper Gastrointestinal Surgery, Hyogo College of Medicine, 1-1 
      Mukogawa-cho, Nishinomiya, Hyogo, 663-8501, Japan.
FAU - Sasako, Mitsuru
AU  - Sasako M
FAU - Mizusawa, Junki
AU  - Mizusawa J
FAU - Hirota, Seiichi
AU  - Hirota S
FAU - Ochiai, Atsushi
AU  - Ochiai A
FAU - Kushima, Ryoji
AU  - Kushima R
FAU - Katai, Hitoshi
AU  - Katai H
FAU - Tanaka, Yoichi
AU  - Tanaka Y
FAU - Fukushima, Norimasa
AU  - Fukushima N
FAU - Nashimoto, Atsushi
AU  - Nashimoto A
FAU - Tsuburaya, Akira
AU  - Tsuburaya A
CN  - Stomach Cancer Study Group of the Japan Clinical Oncology Group
LA  - eng
PT  - Clinical Trial, Phase II
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20140704
PL  - Japan
TA  - Gastric Cancer
JT  - Gastric cancer : official journal of the International Gastric Cancer Association 
      and the Japanese Gastric Cancer Association
JID - 100886238
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Adenocarcinoma/metabolism/mortality/pathology/surgery
MH  - Adult
MH  - Aged
MH  - Female
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence
MH  - Lymph Nodes/pathology
MH  - Lymphatic Metastasis
MH  - Male
MH  - Middle Aged
MH  - Receptor, ErbB-2/genetics/*metabolism
MH  - Stomach Neoplasms/metabolism/mortality/*pathology/surgery
MH  - Survival Rate
FIR - Iwasaki, Y
IR  - Iwasaki Y
FIR - Furukawa, H
IR  - Furukawa H
FIR - Oshita, H
IR  - Oshita H
FIR - Ito, S
IR  - Ito S
FIR - Koeda, K
IR  - Koeda K
FIR - Fujiya, T
IR  - Fujiya T
FIR - Tsujinaka, T
IR  - Tsujinaka T
FIR - Takiuchi, H
IR  - Takiuchi H
FIR - Kurita, A
IR  - Kurita A
FIR - Hase, K
IR  - Hase K
FIR - Kinoshita, T
IR  - Kinoshita T
FIR - Inoue, S
IR  - Inoue S
FIR - Uyama, I
IR  - Uyama I
FIR - Saito, T
IR  - Saito T
FIR - Miyashita, K
IR  - Miyashita K
FIR - Yamaue, H
IR  - Yamaue H
FIR - Ninomiya, M
IR  - Ninomiya M
EDAT- 2014/07/06 06:00
MHDA- 2016/07/07 06:00
CRDT- 2014/07/05 06:00
PHST- 2014/02/01 00:00 [received]
PHST- 2014/06/11 00:00 [accepted]
PHST- 2014/07/05 06:00 [entrez]
PHST- 2014/07/06 06:00 [pubmed]
PHST- 2016/07/07 06:00 [medline]
AID - 10.1007/s10120-014-0398-3 [doi]
PST - ppublish
SO  - Gastric Cancer. 2015 Jul;18(3):467-75. doi: 10.1007/s10120-014-0398-3. Epub 2014 
      Jul 4.